| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1From the University Eye Hospital Lübeck, Lübeck, Germany; the 2Department of Ophthalmology, Friedrich-Alexander Universität, Erlangen, Germany; and the 3The Schepens Eye Research Institute, Harvard Medical School, Boston, Massachusetts.
PURPOSE. To evaluate the impact of photodynamic therapy (PDT) on expression and distribution of vascular endothelial growth factor (VEGF), VEGF receptor (VEGFR)-3, and pigment epithelium–derived factor (PEDF).
METHODS. Eyes of patients scheduled for enucleation due to untreatable malignancy served as study eyes (n = 4), age-matched donor eyes were used as the control (n = 4). PDT using verteporfin with the recommended standard parameters was applied to intact areas of the perimacular region. Lesions were classified by ophthalmoscopy, fluorescein angiography (FA), and indocyanine green angiography (ICGA), as well as light and electron microscopic (LM/EM) histology. Immunolabeling using specific antibodies against VEGF, VEGFR-3, and PEDF was performed in PDT-treated areas, untreated collateral areas in study eyes, and untreated areas of control eyes. Specimens were fixed in 4% paraformaldehyde and 1% glutaraldehyde and embedded in paraffin. Four-micrometer-thick sections were stained using the peroxidase-labeled streptavidin–biotin method.
RESULTS. All PDT-treated areas demonstrated characteristic choroidal hypofluorescence by FA and ICGA. LM/EM histology revealed selective damage of choriocapillary endothelial cells. VEGF was expressed in the endothelial layer of choriocapillaries and focally within larger choroidal vessels in treated areas, but not in untreated areas. Sites with positive VEGF labeling also demonstrated upregulation of VEGFR-3. PEDF expression was localized to retinas in all eyes; however, PEDF staining of choroidal endothelial cells was specific for treated areas of study eyes.
CONCLUSIONS. PDT using verteporfin induces a reproducible angiogenic response in elderly human eyes. VEGF, VEGFR-3, and PEDF expression is enhanced after PDT. Choroidal endothelial cells appear to be the primary site of angiogenic stimulation.
This article has been cited by other articles:
|
|
 |
|
  M. Ju, C. Mailhos, J. Bradley, T. Dowie, M. Ganley, G. Cook, P. Calias, N. Lange, A. P. Adamis, D. T. Shima, et al. Simultaneous but Not Prior Inhibition of VEGF165 Enhances the Efficacy of Photodynamic Therapy in Multiple Models of Ocular Neovascularization Invest. Ophthalmol. Vis. Sci., February 1, 2008; 49(2): 662 - 670. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Mochimaru, N. Nagai, G. Hasegawa, C. Kudo-Saito, T. Yaguchi, Y. Usui, T. Kurihara, T. Koto, S. Satofuka, H. Shinoda, et al. Suppression of Choroidal Neovascularization by Dendritic Cell Vaccination Targeting VEGFR2 Invest. Ophthalmol. Vis. Sci., October 1, 2007; 48(10): 4795 - 4801. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-F. Zuluaga, C. Mailhos, G. Robinson, D. T. Shima, R. Gurny, and N. Lange Synergies of VEGF Inhibition and Photodynamic Therapy in the Treatment of Age-Related Macular Degeneration Invest. Ophthalmol. Vis. Sci., April 1, 2007; 48(4): 1767 - 1772. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A Montero and J. M Ruiz-Moreno Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study Br. J. Ophthalmol., February 1, 2007; 91(2): 131 - 133. [Full Text] [PDF]
|
|
|
|
|
|
R Obata, A Iriyama, Y Inoue, H Takahashi, Y Tamaki, and Y Yanagi Triamcinolone acetonide suppresses early proangiogenic response in retinal pigment epithelial cells after photodynamic therapy in vitro Br. J. Ophthalmol., January 1, 2007; 91(1): 100 - 104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Kosharskyy, N. Solban, S. K. Chang, I. Rizvi, Y. Chang, and T. Hasan A Mechanism-Based Combination Therapy Reduces Local Tumor Growth and Metastasis in an Orthotopic Model of Prostate Cancer. Cancer Res., November 15, 2006; 66(22): 10953 - 10958. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U Chakravarthy, G Soubrane, F Bandello, V Chong, C Creuzot-Garcher, S A Dimitrakos II, J-F Korobelnik, M Larsen, J Mones, D Pauleikhoff, et al. Evolving European guidance on the medical management of neovascular age related macular degeneration. Br. J. Ophthalmol., September 1, 2006; 90(9): 1188 - 1196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Solban, S. K. Pal, S. K. Alok, C. K. Sung, and T. Hasan Mechanistic Investigation and Implications of Photodynamic Therapy Induction of Vascular Endothelial Growth Factor in Prostate Cancer Cancer Res., June 1, 2006; 66(11): 5633 - 5640. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Tatar, E. Kaiserling, A. Adam, F. Gelisken, K. Shinoda, M. Volker, B. A. Lafaut, K. U. Bartz-Schmidt, and S. Grisanti Consequences of verteporfin photodynamic therapy on choroidal neovascular membranes. Arch Ophthalmol, June 1, 2006; 124(6): 815 - 823. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. B. Freund, C. M. Klais, C. M. Eandi, M. D. Ober, D. E. Goldberg, J. A. Sorenson, and L. A. Yannuzzi Sequenced combined intravitreal triamcinolone and indocyanine green angiography-guided photodynamic therapy for retinal angiomatous proliferation. Arch Ophthalmol, April 1, 2006; 124(4): 487 - 492. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Schmidt-Erfurth, S. Michels, and A. Augustin Perspectives on verteporfin therapy combined with intravitreal corticosteroids. Arch Ophthalmol, April 1, 2006; 124(4): 561 - 563. [Full Text] [PDF]
|
|
|
|
|
|
W-M Chan, T Y Y Lai, A L Wong, J-P Tong, D T L Liu, and D S C Lam Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age related macular degeneration: a comparative study. Br. J. Ophthalmol., March 1, 2006; 90(3): 337 - 341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P Kroll and C H Meyer Which treatment is best for which AMD patient? Br. J. Ophthalmol., February 1, 2006; 90(2): 128 - 130. [Full Text] [PDF]
|
|
|
|
|
|
S. Michels, F. Hansmann, W. Geitzenauer, and U. Schmidt-Erfurth Influence of Treatment Parameters on Selectivity of Verteporfin Therapy Invest. Ophthalmol. Vis. Sci., January 1, 2006; 47(1): 371 - 376. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
